Kornimate/medical-research-clean huggingface dataset:
virtual reality for fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia is a frequent chronic pain syndrome almost often affecting women and associating diffuse chronic musculoskeletal pain (for more than 3 months), fatigue and sleep disturbances. other varied functional symptoms are associated with it, in particular cognitive disorders and a feeling of unrested awakening. technological advances in virtual reality have led to recognition by the medical community as a way to improve pain and quality of life for patients. there is a growing body of evidence supporting the use of virtual reality as an adjunct therapy to reduce acute pain in patients during medical procedures in hospital settings. there may also be a role for virtual reality in patients with chronic pain.

current treatments for fibromyalgia (fm) include pharmaceutical pain medications as well as psychological programs with components of cognitive therapy, and activity management. however, pain medications are not fully effective, can be addictive, and can cause hyperalgesia. non-pharmacological treatments for chronic pain may be associated with limiting side effects, technology-based interventions using virtual reality (vr) may be a promising alternative treatment option. there is evidence which shows that vr can be an effective treatment for pain reduction. however, most studies which utilize vr as a method of pain reduction focus on acute pain and studies looking at vr for chronic pain are scarce. investigator will analyze the pain reduction and impact on behavioral mechanisms and cognition with repetitive active vr on fibromyalgia

Eligibility criteria:
inclusion criteria : * patients able to understand and sign the informed consent form for the study * adults aged 18 to 65 years * followed in algology for fibromyalgia pain \> 6 months * with mean pain intensity ≥ 4 exclusion criteria : * history of epilepsy or hypersensitivity to flashing light to limit the risk of virtual reality-induced seizures * previous use of vr for pain (possible bias) * refusal to participate * therapeutic modifications for pain management related to fibromyalgia during the first month of participation

Keywords: fibromyalgia virtual reality chronic pain
the effect of injectable prf vs lll on orthodontic tooth movement

Conditions: Rate of Canine Retraction; Root Resorption

Summary: the purpose of the present study is to compare the effect of injectable platelet fibrin and low level laser therapy on the rate of upper canine retraction, and on root resorption of the canine

the study involves two groups the first group received low level laser at the upper right canine, while the upper left canine act as a control. the second group received injectable platelet rich fibrin at the upper right canine, while the upper left canine act as a control. in each group we will compare rate of canine retraction between both sides, and amount of root resorption also we will compare both groups regarding rate of canine retraction and amount of root resorption

Eligibility criteria:
inclusion criteria: 1. patients with age 18 years or older. 2. presence of all permanent teeth except for the third molar. 3. presence of malocclusion requiring maxillary first premolar extraction such as (class ii division 1 or bimaxillary dentoalveolar protrusion). exclusion criteria: 1. patient with a history of previous orthodontic treatment. 2. medical problems may interfere with orthodontic treatment. 3. bad oral hygiene.
occupational balance, fear and agoraphobia

Conditions: Covid19

Summary: this study was planned to investigate occupational balance, fear of covid-19 and agoraphobia in adults during the covid-19 pandemic.

during the covid-19 pandemic, the occupational balance of individuals change and the sedentary activities preferences, that pose a risk for health, increase.the outbreak also produced effects such as fear of sickness and death in addition to changing daily life and work routines, occupational balance and social participation. this study was planned to investigate occupational balance, fear of covid-19 and agoraphobia in adults during the covid-19 pandemic.

Eligibility criteria:
inclusion criteria: between 19-65 years of age exclusion criteria: \ 65 years old
a study to compare the efficacy and safety of different dosings of olodaterol administered with the respimat® inhaler in patients with moderate to severe asthma

Conditions: Asthma

Summary: this study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).


Eligibility criteria:
inclusion criteria: 1. patients of either sex. 2. aged 18 to 70 years. 3. a current diagnosis and a documented minimum 3 month history of asthma global initiative for asthma (gina) treatment steps 3 and 4. 4. prebronchodilator forced expiratory volume in one second (fev1) \>= 60% predicted and \< 90% predicted according to european coal and steel community (ecsc). 5. increase in fev1 \>=12% and \>=200 ml 15 min. after 400 µg salbutamol (albuterol); 6. stable on medium to high dose inhaled corticosteroids (ics) or low to high dose ics in combination with a long acting beta-adrenergics (laba) for at least 6 weeks prior to screening. stable on ics mono component of the former fixed laba/ics treatment for at least 48 hours prior to visit 1b. exclusion criteria: 1. patients with a significant disease other than asthma. 2. history of frequent seasonal exacerbations of asthma (defined as one or more seasonal exacerbations every year for the past three years). 3. upper respiratory tract infection in the past 3 weeks prior to screening visit 1b. 4. oral or other systemic corticosteroids in the past 6 weeks. 5. patients with allergen desensitization therapy if started within two years, if they are not on an established maintenance regimen characterized by dose adjustments but no further increase to the tolerable maximum in the same course of immunotherapy.
investigator initiated study - asenapine early psychosis

Conditions: Schizophrenia and Disorders With Psychotic Features; Disorders

Summary: we propose a use of a unique facility, the databank at the cndv, to examine the impact of switching subjects to asenapine in an open-label naturalistic setting. this offers the following advantages: i) providing data on a particularly important population, i.e., subjects who are at the inception of treatment for a psychotic disorder and who are likely to remain on a given drug on a long-term basis; ii) its inclusion in a rich clinical setting, with a clinical team dedicated to provide innovative interventions; iii) its naturalistic design, that will allow to obtain data that will be applicable to "real-life" clinical settings; indeed, subjects who will be switched to asenapine within the current project are those we would switch to this drug in our daily practice.


Eligibility criteria:
inclusion criteria: * meeting dsm-iv criteria for schizophrenia (sz) or related sz spectrum psychotic disorders * having provided a consent to include data on our databank,and being able to provide informed consent * willingness to participate to the assessments * being over 18 years of age * being in a clinical situation that warrants switch to asenapine exclusion criteria: * suffering from a primary drug-induced psychosis * being at significant risk for suicide or assault * unstable medical condition * persistence of psychotic symptoms despite adequate treatment to an extent that clozapine would be required * being treated with antipsychotic for 5 years or more * having contraindications(allergy to asenapine) * being pregnant or lactating
efficacy and safety study of 2 different concentrations of cd1579 gels versus vehicle in the treatment of acne vulgaris.

Conditions: Acne Vulgaris

Summary: this study is to assess the efficacy and safety of two concentrations of cd1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the japanese patients.


Eligibility criteria:
inclusion criteria: * men and women at the age of 12 or older at the screening visit. * those with clinical diagnosis of acne vulgaris with more than 20 noninflammatory lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin). exclusion criteria: * those with more than two nodular acne lesions or any cysts. * those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne, or any drug induced acne. * those who have clinically significant abnormal findings or conditions on skin other than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially interfere with study assessments according to investigator's judgment

Keywords: acne vulgaris
reahead: a study to find out whether education improves adherence to dabigatran in people with atrial fibrillation who are younger than 75 years

Conditions: Atrial Fibrillation

Summary: lifelong oral anticoagulant (oac) therapy is the preferred treatment for the prevention of thromboembolic events in the majority of patients with atrial fibrillation (af). adherence to medication is essential for valid treatment for oac therapy. the study aims to explore whether the advanced educational intervention would improve the adherence to dabigatran.


Eligibility criteria:
inclusion criteria: patients can be included if all the following criteria are met: 1. provide written informed consent prior to participation 2. female or male adult patients aged ≥ 20 years and \< 75 years, newly diagnosed with non-valvular atrial fibrillation (nvaf) within 1 month and has newly prescribed with dabigatran on physician's decision before study enrolment. exclusion criteria: patients should not be included if any one of the following criteria is met: 1. contraindication to the use of dabigatran (i.e., active pathological bleeding, history of a serious hypersensitivity reaction to dabigatran \[e.g., anaphylactic reaction or anaphylactic shock\], severely impaired renal function \[creatinine clearance rate (ccr) \< 30 ml/min\], hemorrhagic manifestations, bleeding diathesis, mechanical prosthetic heart valve, congenital or acquired coagulation disorders, organic lesions with bleeding tendency, or concomitantly use systemic ketoconazole, cyclosporine, and itraconazole) 2. participate in other interventional trials currently or in the past 30 days
facilitated release of endogenous enterokines

Conditions: Diabetes Mellitus, Type 2

Summary: the overall objective is to develop therapy for obesity and diabetes that is as effective as gastric bypass surgery but without the cost and safety concerns.

gastric bypass leads to rapid, sustained diabetes remission in the majority of patients who undergo this procedure and is also highly effective therapy for obesity. however, currently \<1% of medically-eligible patients undergo this or other bariatric operations due to cost and safety concerns. the approach is based on data suggesting that the benefit of gastric bypass is largely due to anatomical rearrangement of the intestine which leads to accelerated delivery of nutrients to the jejunum. this rerouting of nutrients stimulates the release of multiple neural, hormonal and enterokine responses that are associated with appetite suppression and improved glucose control. in this pilot proposal the question under investigation is whether repeated rapid delivery of a mixed meal directly to the jejunum can promote weight loss and glucose control.

Eligibility criteria:
inclusion criteria: * type 2 diabetes on oral antidiabetic medication * bmi greater than or equal to 30kg/m2 * a1c less than 9% exclusion criteria: * use of any of the following medications: dipeptide-peptidase iv (dpp-iv) inhibitors (e.g., sitagliptin), glp-1 analogs (e.g., exenatide) or medication that could alter glucose tolerance (e.g. steroids) * contraindication to tube (e.g. prior upper gastrointestinal bleed, or history of easy bleeding, altered foregut anatomy due to obstruction or surgery) * known cardiovascular disease other than controlled hypertension. * pregnancy or unwilling to take contraception * active esophagitis * known hiatal hernia * active gastric ulcer and/or duodenal ulcers, * previous restrictive surgery of the gastrointestinal tract * crohn's disease * active cancer * history of gastrointestinal hemorrhage * known upper gastrointestinal lesions with potential to bleed * use of nsaids or anticoagulants * psychiatric disorders other than mild depression * likely inability to adhere to study protocol including alcohol or drug dependent patients * type i diabetes, * liver, kidney or multi-organ dysfunction. * known eating disorders * inability to attend scheduled or unanticipated study visits * known prior abdominal problems or operations that could lead to adhesions or strictures and that could prevent the spontaneous passage of a 10 french jejunal tube if it were to dislodge distally.

Keywords: obesity diabetes mellitus, type 2 nutrient
nlp to aid in the evaluation and diagnosis of fgids

Conditions: Functional Gastrointestinal Disorders

Summary: the study has two arms, where the same natural language processing (nlp) and probabilistic graphical modeling technology will be utilized on patients' report of symptoms in both arms. the clinical arm is focused on patients presenting for consultation with a gastroenterologist. the endoscopy arm is focused generally on patients presenting for a diagnostic endoscopy, with the goal of capturing functional gastrointestinal disorder (fgid) patients prior to diagnosis.


Eligibility criteria:
inclusion criteria: * scheduled for consult in the motility clinic in the mgh gastroenterology unit or for diagnostic endoscopy in the mgh gastroenterology unit * patient must agree to have their interactions audio-recorded * informed consent form signed by the subjects exclusion criteria: * non-native english speaker * patients unable to communicate their own symptoms
effect of dietary sodium and potassium citrate on renal mineral handling

Conditions: Kidney Stone

Summary: this study intends to characterize the affect of sodium and potassium citrate in the diet on renal function.


Eligibility criteria:
inclusion criteria: * age 18 - 70, approximately equal numbers of men and women * studied by endoscopy with complete papillary mapping and grading * stone formers exclusion criteria: * patients with primary renal diseases or renal impairment (egfr \< 90), or medical conditions such as diabetes, or systemic diseases or medications that alter calcium metabolism * patients with known bladder voiding problems
construction-lbd (constructional apraxia in alzheimer's disease (ad) and lewy body's dementia (lbd))

Conditions: Alzheimer's Disease; Lewy Body's Dementia

Summary: alzheimer's disease (ad) and lewy body's dementia (lbd) are two frequent neurodegenerative pathologies. they differ in their expression, their evolution but share same features which make their diagnosis uneasy. constructional apraxia has been described in both disease.the underlying mechanisms have been less studied and could be different in ad and lbd. the definition of the constructional apraxia is purely descriptive and few models are inconclusive. it is admitted that drawing tasks involve visuo-perceptive and visuo-spatial abilities, executive functions and working memory as well as purely "constructive" skills. regarding to different studies, visuo-perceptive abilities are more severely impaired in lbd than in ad and are considered as an early onset sign of the disease. executive functions deficits are documented in ad and ldb and could contribute to the drawing impairment. it is possible to compensate the planning disorders in giving patient the best strategy to use. if drawing impairment persists, they should result of others mechanisms like visuo-perception, visuo-spatial or constructive deficits. the investigators suggest that giving the best planning strategy will help more ad patients who are supposed to fail in raison of an executive impairment, than the ldb group who is supposed to present visuo-perceptive deficits. an mri will be proposed to study the cerebral areas involved in constructional apraxia.


Eligibility criteria:
inclusion criteria: * alzheimer's disease or lewy bodies dementia * ≥ 45 years * the cognitive impairment is mild to moderate * french speaker * a caregiver is present * an informed consent is signed by the patient and the p.i. exclusion criteria: * mri contraindication * other neurological disease (ftd, brain tumor, vascular disease...) * psychiatric disease (schizophrenia, major depression, psychotic disorders, melancholia...) * patient who doesn't want to be informed in case of the discovery of an abnormality * view or audition deficits, or motor disability which can interfere with the cognitive testing * patient participating to an exclusive protocol or in the period of exclusion * pregnant woman * person under an administrative or legal measure of liberty privation * person under a legal measure of protection or under administrative supervision * person unable to give his consent
bringing what works to youth in corrections: a trauma intervention

Conditions: Post-Traumatic Stress Disorder

Summary: youth with mental illnesses are disproportionately represented in juvenile correctional facilities and limited evidence exists about effective treatments in this setting. this study will adapt trauma-focused cognitive behavioral therapy (tf-cbt), a treatment found to be efficacious in community settings, to the correctional setting and study the feasibility of its implementation. conducted within texas youth correctional facilities, the findings will be rapidly disseminated in the state. the goal is to enhance the tf-cbt approach to meet the unique needs of incarcerated youth and the correctional system, one of the priorities outlined in the national institute of mental health strategic plan.


Eligibility criteria:
inclusion criteria: * evidence of one or more significant traumatic life events * current diagnosis of one of the following: * post traumatic stress disorder * major depressive disorder * dysthymia * generalized anxiety disorder * social phobia * panic disorder * trauma symptom severity scores of 25 or greater. exclusion criteria: * expected release date or transfer date within 5 months from study enrollment date * current inclusion in the sex offender treatment program * intellectual quotient (iq) less than 70 * current high risk of suicidality * current symptoms of active psychosis

Keywords: post traumatic stress disorder major depressive disorder dysthymia generalized anxiety disorder social phobia panic disorder
registry of chronic subdural hematoma

Conditions: Chronic Subdural Hematoma; Registry

Summary: the goal of this observational study is to better understand how chronic subdural hematoma (csdh) progresses and how patients are treated and cared for. the study focuses on three main questions: 1. what are the characteristics of patients with csdh when they are diagnosed? 2. what treatments do patients with csdh receive? 3. what are the outcomes for patients with csdh, including their functional ability, cognitive health, and neurological status? participants will receive their usual standard treatment. as part of the study, they will complete a brief telephone interview three months after their treatment.

rationale: chronic subdural hematoma (csdh) is a common condition encountered by neurologists and neurosurgeons. while guidelines for the management of csdh have recently been developed, high-quality evidence to inform these recommendations, particularly level i evidence from randomized clinical trials (rcts), is awaited. significant variability in the management of csdh persists at international, national, and inter-hospital levels. to further refine and implement evidence-based guidelines, a detailed understanding of current clinical practices and their associated outcomes is essential. objective: to describe the baseline characteristics, treatment strategies, and outcomes of patients diagnosed with chronic subdural hematoma. study design: a prospective, observational multicenter cohort study. study population: all adult patients diagnosed with chronic subdural hematoma. main study parameters/endpoints: the primary endpoint is functional outcome, measured by the modified rankin scale (mrs) at 3 months. secondary endpoints, also assessed at 3 months, include recurrence, mortality, complications, hospital length of stay, markwalder grading scale (mgs), modified national institutes of health stroke scale (mnihss), and telephone interview for cognitive status (tics). nature and extent of the burden and risks associated with participation, benefit and group relatedness: patients will be treated in accordance with standard clinical practice. study participation imposes minimal additional burden, consisting of a single telephone interview at three months, estimated to take approximately 10 minutes. the findings from this registry are expected to benefit future csdh patients by informing evidence-based guidelines and improving care practices.

Eligibility criteria:
inclusion criteria: * patients diagnosed with csdh * 18 years or older exclusion criteria: * patients who do not consent to participate in the registry

Keywords: chronic subdural hematoma traumatic brain injury registry treatment outcome burr hole drainage modified rankin scale
comparison of the efficacy of topical ibuprofen to oral ibuprofen in adolescent athletes

Conditions: Soft Tissue Injury

Summary: this study was made to compare the efficacy of topical ibuprofen in gel form with oral ibuprofen in the treatment of sub-acute soft tissue injuries while comparing the tolerability of the delivery methods


Eligibility criteria:
inclusion criteria: * age 12-19yo * soft tissue injury or flare up of soft tissue injury within 10 days to 8 weeks exclusion criteria: * known hypersensitivity to aspirin or any nsaid, * allergy to eggs or egg products * history of asthma, renal disease, gi disease, active or suspected bleeding peptic ulcer (past or present), anemia, hypertension, other systemic disease significantly affecting liver or renal function * serious injury within six months * currently on anticoagulants * pregnant or lactating females * active arthritis in affected limb * open wounds, infected skin or fractures * opioid use within 7 days * severe psychological disorder * prior topical medication applied to the painful region/area of study

Keywords: soft tissue injuries topical ibuprofen adolescent athletes